STOCK TITAN

[Form 4] Virtu Financial, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Rockwell Medical, Inc. (RMTI) – Form 4/A amendment reports that Senior Vice President & Chief Financial Officer Jesse Neri sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82 per share. The filing clarifies that the trade was executed pursuant to a Rule 10b5-1 trading plan adopted on 13-Dec-2024; this checkbox was inadvertently left blank in the original Form 4 filed 02-Jul-2025.

After the disposition, Neri directly owns 126,614 shares of RMTI. No derivative securities were bought or sold, and there are no other changes to his ownership stake.

The transaction represents roughly 0.7 % of the executive’s reported holdings and is immaterial relative to the company’s total shares outstanding. Because the sale was pre-arranged and the amendment is purely administrative, the filing carries limited fundamental significance but may still interest investors who monitor insider activity for sentiment cues.

Rockwell Medical, Inc. (RMTI) – Emendamento al Modulo 4/A segnala che il Senior Vice President e Chief Financial Officer Jesse Neri ha venduto 886 azioni ordinarie il 01-lug-2025 ad un prezzo medio ponderato di $0,82 per azione. Il documento specifica che la transazione è stata effettuata in base a un piano di trading Rule 10b5-1 adottato il 13-dic-2024; questa casella era stata lasciata erroneamente vuota nel Modulo 4 originale presentato il 02-lug-2025.

Dopo la vendita, Neri possiede direttamente 126.614 azioni di RMTI. Non sono stati acquistati o venduti titoli derivati e non ci sono altre variazioni nella sua partecipazione azionaria.

La transazione rappresenta circa il 0,7% delle partecipazioni dichiarate dell’esecutivo ed è irrilevante rispetto al totale delle azioni in circolazione della società. Poiché la vendita era predefinita e l’emendamento è di natura puramente amministrativa, il documento ha una significatività fondamentale limitata, ma potrebbe comunque interessare gli investitori che monitorano l’attività degli insider per segnali di sentiment.

Rockwell Medical, Inc. (RMTI) – Enmienda al Formulario 4/A informa que el Vicepresidente Senior y Director Financiero Jesse Neri vendió 886 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $0.82 por acción. El documento aclara que la operación se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado el 13-dic-2024; esta casilla se dejó inadvertidamente en blanco en el Formulario 4 original presentado el 02-jul-2025.

Después de la venta, Neri posee directamente 126,614 acciones de RMTI. No se compraron ni vendieron valores derivados y no hay otros cambios en su participación accionaria.

La transacción representa aproximadamente el 0,7% de las participaciones reportadas del ejecutivo y es insignificante en relación con el total de acciones en circulación de la empresa. Dado que la venta fue preestablecida y la enmienda es puramente administrativa, el documento tiene una relevancia fundamental limitada, aunque puede interesar a los inversores que monitorean la actividad interna para obtener señales sobre el sentimiento del mercado.

Rockwell Medical, Inc. (RMTI) – Form 4/A 수정 보고서에 따르면 수석 부사장이자 최고재무책임자인 제시 네리(Jesse Neri)2025년 7월 1일886주의 보통주를 주당 가중평균 가격 $0.82에 매도했습니다. 이 제출서는 해당 거래가 2024년 12월 13일 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 원래 2025년 7월 2일 제출된 Form 4에서 이 체크박스가 실수로 비워져 있었음을 명확히 합니다.

매도 후 네리는 RMTI 주식 126,614주를 직접 보유하고 있습니다. 파생증권의 매매는 없었으며, 그의 소유 지분에 다른 변경 사항도 없습니다.

이번 거래는 경영진 보고 지분의 약 0.7%에 해당하며 회사의 전체 발행 주식수에 비해 미미한 규모입니다. 매각이 사전에 계획된 것이고 수정 제출이 단순 행정적 성격이므로, 이번 제출은 기본적 중요성은 제한적이나 내부자 활동을 감시하는 투자자들에게는 시장 심리 신호로서 관심을 끌 수 있습니다.

Rockwell Medical, Inc. (RMTI) – Amendement du formulaire 4/A rapporte que le Vice-Président Senior et Directeur Financier Jesse Neri a vendu 886 actions ordinaires le 01-juil-2025 à un prix moyen pondéré de 0,82 $ par action. Le dépôt précise que la transaction a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 13-déc-2024 ; cette case avait été laissée vide par inadvertance dans le formulaire 4 original déposé le 02-juil-2025.

Après cette cession, Neri détient directement 126 614 actions de RMTI. Aucun titre dérivé n’a été acheté ou vendu, et il n’y a pas d’autres modifications dans sa participation.

La transaction représente environ 0,7 % des avoirs déclarés de l’exécutif et est négligeable par rapport au nombre total d’actions en circulation de la société. Étant donné que la vente était préalablement organisée et que l’amendement est de nature purement administrative, le dépôt a une signification fondamentale limitée mais peut néanmoins intéresser les investisseurs qui surveillent l’activité des initiés pour détecter des indices de sentiment.

Rockwell Medical, Inc. (RMTI) – Änderung des Formulars 4/A berichtet, dass der Senior Vice President und Chief Financial Officer Jesse Neri am 01. Juli 2025 886 Stammaktien zu einem gewichteten Durchschnittspreis von 0,82 $ pro Aktie verkauft hat. Die Einreichung stellt klar, dass der Handel gemäß einem am 13. Dezember 2024 angenommenen Rule 10b5-1 Handelsplan erfolgte; dieses Kontrollkästchen wurde im ursprünglichen Formular 4 vom 02. Juli 2025 versehentlich nicht ausgefüllt.

Nach der Veräußerung besitzt Neri direkt 126.614 Aktien von RMTI. Es wurden keine derivativen Wertpapiere gekauft oder verkauft, und es gibt keine weiteren Änderungen seiner Beteiligung.

Die Transaktion entspricht etwa 0,7 % der gemeldeten Beteiligungen des Managers und ist im Vergleich zum gesamten ausstehenden Aktienbestand des Unternehmens unerheblich. Da der Verkauf vorab geplant war und die Änderung rein administrativer Natur ist, hat die Einreichung eine begrenzte fundamentale Bedeutung, könnte aber dennoch für Investoren interessant sein, die Insideraktivitäten zur Einschätzung der Marktsentiments beobachten.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Minor insider sale under 10b5-1 plan; administrative amendment; neutral investor impact.

The amended Form 4 simply documents that the 886-share sale by CFO Jesse Neri occurred within a pre-scheduled Rule 10b5-1 framework, mitigating any concerns about opportunistic timing. The disposal equals less than 1 % of his holdings and is insignificant compared with Rockwell Medical’s float. No new economic transactions or derivative positions are disclosed, and beneficial ownership remains sizable at 126,614 shares. Given the small volume and procedural nature of the amendment, I view the event as neutral for valuation and governance risk assessments.

Rockwell Medical, Inc. (RMTI) – Emendamento al Modulo 4/A segnala che il Senior Vice President e Chief Financial Officer Jesse Neri ha venduto 886 azioni ordinarie il 01-lug-2025 ad un prezzo medio ponderato di $0,82 per azione. Il documento specifica che la transazione è stata effettuata in base a un piano di trading Rule 10b5-1 adottato il 13-dic-2024; questa casella era stata lasciata erroneamente vuota nel Modulo 4 originale presentato il 02-lug-2025.

Dopo la vendita, Neri possiede direttamente 126.614 azioni di RMTI. Non sono stati acquistati o venduti titoli derivati e non ci sono altre variazioni nella sua partecipazione azionaria.

La transazione rappresenta circa il 0,7% delle partecipazioni dichiarate dell’esecutivo ed è irrilevante rispetto al totale delle azioni in circolazione della società. Poiché la vendita era predefinita e l’emendamento è di natura puramente amministrativa, il documento ha una significatività fondamentale limitata, ma potrebbe comunque interessare gli investitori che monitorano l’attività degli insider per segnali di sentiment.

Rockwell Medical, Inc. (RMTI) – Enmienda al Formulario 4/A informa que el Vicepresidente Senior y Director Financiero Jesse Neri vendió 886 acciones ordinarias el 01-jul-2025 a un precio promedio ponderado de $0.82 por acción. El documento aclara que la operación se realizó conforme a un plan de negociación bajo la Regla 10b5-1 adoptado el 13-dic-2024; esta casilla se dejó inadvertidamente en blanco en el Formulario 4 original presentado el 02-jul-2025.

Después de la venta, Neri posee directamente 126,614 acciones de RMTI. No se compraron ni vendieron valores derivados y no hay otros cambios en su participación accionaria.

La transacción representa aproximadamente el 0,7% de las participaciones reportadas del ejecutivo y es insignificante en relación con el total de acciones en circulación de la empresa. Dado que la venta fue preestablecida y la enmienda es puramente administrativa, el documento tiene una relevancia fundamental limitada, aunque puede interesar a los inversores que monitorean la actividad interna para obtener señales sobre el sentimiento del mercado.

Rockwell Medical, Inc. (RMTI) – Form 4/A 수정 보고서에 따르면 수석 부사장이자 최고재무책임자인 제시 네리(Jesse Neri)2025년 7월 1일886주의 보통주를 주당 가중평균 가격 $0.82에 매도했습니다. 이 제출서는 해당 거래가 2024년 12월 13일 채택된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 원래 2025년 7월 2일 제출된 Form 4에서 이 체크박스가 실수로 비워져 있었음을 명확히 합니다.

매도 후 네리는 RMTI 주식 126,614주를 직접 보유하고 있습니다. 파생증권의 매매는 없었으며, 그의 소유 지분에 다른 변경 사항도 없습니다.

이번 거래는 경영진 보고 지분의 약 0.7%에 해당하며 회사의 전체 발행 주식수에 비해 미미한 규모입니다. 매각이 사전에 계획된 것이고 수정 제출이 단순 행정적 성격이므로, 이번 제출은 기본적 중요성은 제한적이나 내부자 활동을 감시하는 투자자들에게는 시장 심리 신호로서 관심을 끌 수 있습니다.

Rockwell Medical, Inc. (RMTI) – Amendement du formulaire 4/A rapporte que le Vice-Président Senior et Directeur Financier Jesse Neri a vendu 886 actions ordinaires le 01-juil-2025 à un prix moyen pondéré de 0,82 $ par action. Le dépôt précise que la transaction a été réalisée conformément à un plan de trading Rule 10b5-1 adopté le 13-déc-2024 ; cette case avait été laissée vide par inadvertance dans le formulaire 4 original déposé le 02-juil-2025.

Après cette cession, Neri détient directement 126 614 actions de RMTI. Aucun titre dérivé n’a été acheté ou vendu, et il n’y a pas d’autres modifications dans sa participation.

La transaction représente environ 0,7 % des avoirs déclarés de l’exécutif et est négligeable par rapport au nombre total d’actions en circulation de la société. Étant donné que la vente était préalablement organisée et que l’amendement est de nature purement administrative, le dépôt a une signification fondamentale limitée mais peut néanmoins intéresser les investisseurs qui surveillent l’activité des initiés pour détecter des indices de sentiment.

Rockwell Medical, Inc. (RMTI) – Änderung des Formulars 4/A berichtet, dass der Senior Vice President und Chief Financial Officer Jesse Neri am 01. Juli 2025 886 Stammaktien zu einem gewichteten Durchschnittspreis von 0,82 $ pro Aktie verkauft hat. Die Einreichung stellt klar, dass der Handel gemäß einem am 13. Dezember 2024 angenommenen Rule 10b5-1 Handelsplan erfolgte; dieses Kontrollkästchen wurde im ursprünglichen Formular 4 vom 02. Juli 2025 versehentlich nicht ausgefüllt.

Nach der Veräußerung besitzt Neri direkt 126.614 Aktien von RMTI. Es wurden keine derivativen Wertpapiere gekauft oder verkauft, und es gibt keine weiteren Änderungen seiner Beteiligung.

Die Transaktion entspricht etwa 0,7 % der gemeldeten Beteiligungen des Managers und ist im Vergleich zum gesamten ausstehenden Aktienbestand des Unternehmens unerheblich. Da der Verkauf vorab geplant war und die Änderung rein administrativer Natur ist, hat die Einreichung eine begrenzte fundamentale Bedeutung, könnte aber dennoch für Investoren interessant sein, die Insideraktivitäten zur Einschätzung der Marktsentiments beobachten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GRANO JOSEPH J JR

(Last) (First) (Middle)
C/O VIRTU FINANCIAL, INC.
1633 BROADWAY

(Street)
NEW YORK NY 10019

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Virtu Financial, Inc. [ VIRT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock 07/03/2025 M 6,681 A (1) 38,822 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (2) 07/01/2025 A 3,392 (3) (3) Class A common stock 3,392 $0 10,073 D
Restricted Stock Unit (2) 07/03/2025 M 6,681 (4) (4) Class A common stock 6,681 $0 3,392 D
Explanation of Responses:
1. Shares of Class A common stock issued in settlement of vested restricted stock units ("RSUs") granted under the Issuer's Amended and Restated 2015 Management Incentive Plan.
2. Each RSU is granted under the Issuer's Amended and Restated 2015 Management Incentive Plan and represents a contingent right to receive one share of Class A common stock of the Issuer.
3. The RSUs vest on July 1, 2026.
4. The RSUs vested on July 3, 2025.
Remarks:
Justin Waldie, as Attorney-in-Fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rockwell Medical (RMTI) shares did CFO Jesse Neri sell?

He sold 886 common shares on 01-Jul-2025 at a weighted-average price of $0.82.

What is the CFO’s remaining ownership after the transaction?

Following the sale, Jesse Neri directly owns 126,614 RMTI shares.

Was the sale executed under a Rule 10b5-1 trading plan?

Yes. The Form 4/A confirms the sale was made pursuant to a Rule 10b5-1 plan adopted on 13-Dec-2024.

Does the Form 4/A disclose any derivative securities transactions?

No. No options, warrants, or other derivatives were acquired or disposed of in this filing.

Why was the Form 4 amended?

The amendment checks the box indicating the sale was under a 10b5-1 plan; no economic details were changed.
Virtu Financial

NYSE:VIRT

VIRT Rankings

VIRT Latest News

VIRT Latest SEC Filings

VIRT Stock Data

3.73B
80.42M
5.98%
88.99%
3.16%
Capital Markets
Security Brokers, Dealers & Flotation Companies
Link
United States
NEW YORK